Please login to the form below

Not currently logged in
Email:
Password:

Xalkori

This page shows the latest Xalkori news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Health and social care still divided, Opdivo rejected in bladder cancer, Xalkori extends reach

Daily Brief: Health and social care still divided, Opdivo rejected in bladder cancer, Xalkori extends reach

Daily Brief: Health and social care still divided, Opdivo rejected in bladder cancer, Xalkori extends reach. ... Expanded use of Xalkori approved in England. Also released today was final NICE guidance recommending Pfizer’s Xalkori (crizotinib) to

Latest news

  • Pfizer files third-gen ALK inhibitor for lung cancer Pfizer files third-gen ALK inhibitor for lung cancer

    Pfizer has filed for approval of its third-generation ALK inhibitor lorlatinib, a follow-up to its first-generation Xalkori product which is facing increasing competition. ... Pfizer notes that lorlatinib has shown activity in almost all known clinically

  • Roche gets FDA OKs for Alecensa and Zelboraf Roche gets FDA OKs for Alecensa and Zelboraf

    cancer. Alecensa (alectinib) has been approved for second-line use after Pfizer’s Xalkori (crizotinib) in patients with ALK-positive non-small cell lung cancer (NSCLC) in the US since the ... The approval is based on the results of the ALEX study,

  • Roche wins CHMP nod for Alecensa licence extensions Roche wins CHMP nod for Alecensa licence extensions

    The Committee also recommended Alecensa’s licence be extended to encompass second-line therapy in cases where Pfizer ’s personalised NSCLC treatment Xalkori (crizotinib) can’t be used.

  • UK is first to receive Roche's rare lung cancer drug UK is first to receive Roche's rare lung cancer drug

    Data from the study showed that patients taking Alecensa had significantly prolonged progression-free survival when compared with Pfizer’s Xalkori (crizotinib), reducing risk of progression/death by 53%.

  • EMA starts firming up its stance on personalised medicines EMA starts firming up its stance on personalised medicines

    As more treatments like Pfizer’s Xalkori, Vertex’s Kalydeco and Boehringer Ingelheim’s Giotrif/Gilotrif come to market it also wants to better define those patients that will benefit from

More from news
Approximately 22 fully matching, plus 52 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2014 Pharma deals during November 2014

    In addition Merck KGaA also gets the right to co-promote Xalkori in the US and other "key" markets.

  • Oncology drugs under AMNOG: part two Oncology drugs under AMNOG: part two

    of Xalkori, below - the drug can achieve accelerated approval on the basis of an interim analysis or phase II data before OS is established. ... Outcome. Xalkori(crizotinib) in NSCLC. No OS benefit shown but positive data in morbidity (symptom improvement

  • Who tops the pharma list? Who tops the pharma list?

    Pfizer's Xalkori is just one example of this.”. Alongside oncology, treatments for immunology and metabolic diseases rank among the fastest-growing therapeutic classifications.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics